LSB
LakeShore Biopharma
About: LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
Employees: 758
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0.34% more ownership
Funds ownership: 1.69% [Q3] → 2.04% (+0.34%) [Q4]
14% less funds holding
Funds holding: 7 [Q3] → 6 (-1) [Q4]
40% less capital invested
Capital invested by funds: $2.23M [Q3] → $1.34M (-$887K) [Q4]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Research analyst outlook
We haven’t received any recent analyst ratings for LSB.
Financial journalist opinion
Neutral
PRNewsWire
1 week ago
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING , April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province.
Neutral
PRNewsWire
4 months ago
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY Gross margin increased to 82.6% from 80.9% in the same period of FY2024 Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY Recorded net income of RMB 20.6 million, and adjusted net income[1] (Non-GAAP) of RMB 30.4 million, compared to net loss and adjusted net loss[1] (Non-GAAP) of RMB 174.5 million in the same period of FY2024 BEIJING , Dec. 19, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the first six months ended September 30, 2024 ("FY2025H1").
Neutral
GlobeNewsWire
4 months ago
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading global biopharmaceutical company focused on the innovation and production of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Shenyang Municipal Public Security Bureau in China (the “Bureau”) has initiated criminal investigations into actions taken by former chairman of the board of directors Yi Zhang (“Former Chairman”).
Neutral
PRNewsWire
6 months ago
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
GAITHERSBURG, Md., Oct. 29, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a written notice (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated October 21, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth under the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").
Neutral
PRNewsWire
6 months ago
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
GAITHERSBURG, Md. , Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has been granted approval for a Phase III clinical trial (the "Trial") by the National Medical Products Administration (NMPA) in China to explore the immunogenicity and safety of a simplified four-dose regimen for its YSJA rabies vaccine which is the first generation of the Company's rabies vaccine and has sold more than 100M doses since its market approval.
Neutral
PRNewsWire
6 months ago
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
GAITHERSBURG, Md. , Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it is providing financial guidance for the half year of its fiscal year of 2025 and reaffirming its financial guidance for the full year of its fiscal year 2025 ending on March 31, 2025 ("Fiscal Year 2025"), underlining the Company's strong execution and positive business momentum.
Neutral
PRNewsWire
7 months ago
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
GAITHERSBURG, Md. , Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on September 27, 2024 (Beijing Time) virtually via a Zoom video conference call.
Neutral
PRNewsWire
7 months ago
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
GAITHERSBURG, Md. , Sept. 10, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 10:00 a.m.
Neutral
PRNewsWire
7 months ago
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md. , Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd.
Neutral
PRNewsWire
8 months ago
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
Gross margin increased to 79.5%; product pipeline continues to advance Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025 GAITHERSBURG, Md. , Aug. 15, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd.
Charts implemented using Lightweight Charts™